A scalable engineered cell system for producing clinical-grade virus-like particles to create gene-edited CAR-T and CAR-NK cells

CRISPR-Cas9 has transformed the engineering of chimeric antigen receptor T (CAR-T) and chimeric antigen receptor NK (CAR-NK) cells.

• Current manufacturing methods for CAR-T and CAR-NK cells involve high costs and variability.
• Viral and electroporation-based approaches face stringent regulatory requirements.
• Clinical translation of these engineered cells is limited by manufacturing challenges.

Simplified